FDA Approves First Gene Therapy for Congenital Deafness, Restoring Hearing in Children

The short version is this: the FDA has approved the first-ever gene therapy to treat a genetic form of deafness. The one-time surgical infusion, marketed as Otarmeni, restores natural hearing in children born with a specific genetic mutation. For families navigating a diagnosis of profound congenital hearing loss, the approval introduces a fundamentally new option—one that fixes the biological hardware itself rather than relying on external devices.[1][2]

For decades, the only medical interventions for congenital deafness were hearing aids, which amplify sound, or cochlear implants, which bypass the ear's natural structures to stimulate the auditory nerve directly. While transformative, cochlear implants require lifelong hardware dependence and deliver an artificial representation of sound. Otarmeni takes a different approach, aiming to restore the ear's natural physiological function.[3][6]

The treatment targets a rare condition caused by mutations in the OTOF gene. In a healthy ear, sound waves vibrate the inner ear's hair cells. These cells rely on a protein called otoferlin to translate those mechanical vibrations into chemical signals that the auditory nerve can carry to the brain. Children with biallelic OTOF mutations do not produce otoferlin. The ear's microphone works perfectly, but the cable connecting it to the brain is effectively unplugged.[1][6]

Otarmeni works by delivering a functional copy of the OTOF gene directly into the cochlea. Because genes cannot simply be dropped into the body, the therapy uses a modified, harmless adeno-associated virus (AAV1) as a delivery vehicle. Once the viral vector enters the inner hair cells, the new gene instructs the cells to begin manufacturing the missing otoferlin protein, re-establishing the connection between the ear and the brain.[1][3]

The clinical evidence driving the approval is striking. In the pivotal CHORD trial, which enrolled infants, children, and adolescents, 80 percent of evaluable participants experienced clinically meaningful hearing improvements at 24 weeks. With longer follow-up, 42 percent of participants achieved normal hearing, including the ability to perceive whispers—a level of auditory fidelity that is notoriously difficult to achieve with implants.[2][4]

Recognizing the magnitude of the breakthrough, the FDA expedited the review process under its Commissioner's National Priority Voucher program, clearing the therapy in just 61 days. It marks the first gene therapy approved under the pilot program and ties for the fastest biologics license application approval in modern FDA history.[1]

In an unusual move for the notoriously expensive gene therapy market, Regeneron Pharmaceuticals announced it will provide Otarmeni at no cost to eligible patients in the United States. While families may still face out-of-pocket costs for the surgical administration and anesthesia, the drug itself will be free, removing a massive financial barrier that typically accompanies one-time genetic cures.[2][4][5]

However, the therapy is highly specific and will not apply to most deaf children. OTOF-related deafness accounts for just 2 to 8 percent of inherited, non-syndromic hearing loss cases—roughly 200,000 people worldwide. To qualify for the treatment, patients must have preserved outer hair cell function and no prior cochlear implant in the treated ear.[1][3][6]

Uncertainty also remains regarding the long-term durability of the treatment. Because this is the first therapy of its kind, researchers do not yet know if the restored hearing will last a lifetime or if the effect will wane over decades. The FDA's accelerated approval is contingent on Regeneron providing ongoing data to verify the treatment's lasting effects on speech development and quality of life.[1][3]

Beyond the clinical data, the approval intersects with complex cultural conversations. While many parents and clinicians celebrate the medical milestone, advocates within the Deaf community emphasize that deafness is a cultural identity with its own rich language and heritage, not a disease requiring a cure. The availability of a genetic fix introduces profound new choices for parents of deaf infants.

Ultimately, the approval of Otarmeni establishes a critical proof of concept. By demonstrating that a viral vector can safely and effectively deliver a working gene to the inner ear, the therapy paves the way for a new generation of genetic medicines targeting other forms of inherited hearing loss.[4][5]